Liu Cui, Liu Yameng, Tian Jun, Zhang Shengli, Li Xinmiao, Zhai Xiemin, Feng Qiang
Department of Respiratory Medicine.
Quality Control Office, Cangzhou People's Hosptial, Cangzhou.
Medicine (Baltimore). 2020 May;99(20):e20122. doi: 10.1097/MD.0000000000020122.
The present study aimed to investigate SRY-box transcription factor 30 (SOX30) expression in nonsmall-cell lung cancer (NSCLC) tumor tissues and adjacent noncancerous tissues, and further explore the correlation of tumor SOX30 expression with clinical characteristics and survival profiles in patients with NSCLC.Totally, 365 patients with NSCLC who underwent resection were screened, and SOX30 expression was detected in their tumor tissues and adjacent noncancerous tissues via immunohistochemistry (IHC) assay, which was assessed by a semiquantitative method considering the multiplying staining intensity score and staining density score. According to the tumor SOX30 expression, patients were categorized as tumor SOX30 low (IHC score ≤3) and high (IHC score 4-12) patients, the latter were further divided into tumor SOX30 high+ (IHC score 4-6), high++ (IHC score 7-9), and high+++ (IHC score 10-12) patients.SOX30 was downregulated in NSCLC tumor tissues compared with adjacent noncancerous tissues. Meanwhile, tumor SOX30 high expression associated with well differentiation, absent lymph node metastasis, decreased TNM stage, but did not associated with age, gender, history of smoke and drink, hypertension, hyperlipidemia, diabetes, tumor size, or carcinoembryonic antigen level. Both accumulating disease-free survival and overall survival were the longest in tumor SOX30 high+++ patients, followed by tumor SOX30 high++ patients, and tumor SOX30 high+ patients, and the shortest in tumor SOX30 low patients. Besides, tumor SOX30 high expression was an independent predictor for longer disease-free survival and overall survival.Tumor SOX30 exhibits the potential to be a novel biomarker for survival prediction of patients with NSCLC.
本研究旨在调查SRY盒转录因子30（SOX30）在非小细胞肺癌（NSCLC）肿瘤组织及癌旁非肿瘤组织中的表达情况，并进一步探讨肿瘤SOX30表达与NSCLC患者临床特征及生存情况的相关性。共筛选出365例行手术切除的NSCLC患者，通过免疫组织化学（IHC）检测其肿瘤组织及癌旁非肿瘤组织中的SOX30表达，采用半定量方法评估，综合染色强度评分和染色密度评分。根据肿瘤SOX30表达情况，将患者分为肿瘤SOX30低表达组（IHC评分≤3）和高表达组（IHC评分4 - 12），高表达组进一步分为肿瘤SOX30高 + 组（IHC评分4 - 6）、高 ++ 组（IHC评分7 - 9）和高 +++ 组（IHC评分10 - 12）。与癌旁非肿瘤组织相比，NSCLC肿瘤组织中SOX30表达下调。同时，肿瘤SOX30高表达与高分化、无淋巴结转移、TNM分期降低相关，但与年龄、性别、吸烟饮酒史、高血压、高脂血症、糖尿病、肿瘤大小或癌胚抗原水平无关。肿瘤SOX30高 +++ 组患者的无病生存期和总生存期累积时间最长，其次是肿瘤SOX30高 ++ 组患者和肿瘤SOX30高 + 组患者，肿瘤SOX30低表达组患者最短。此外，肿瘤SOX30高表达是无病生存期和总生存期延长的独立预测因素。肿瘤SOX30具有成为NSCLC患者生存预测新生物标志物的潜力。
